Nanomaterials in targeting amyloid-β oligomers: current advances and future directions for Alzheimer's disease diagnosis and therapy

• Shiwani Randhawa,
• Trilok Chand Saini,
• Manik Bathla,
• Rahul Bhardwaj,
• Rubina Dhiman and
• Amitabha Acharya

Beilstein J. Nanotechnol. 2025, 16, 561–580, doi:10.3762/bjnano.16.44

• internalized, AβOs activate N-methyl-ᴅ-aspartate-type glutamate receptors (NMDARs) located on neuronal membranes. This activation triggers endoplasmic reticulum (ER) stress through the stimulation of phospholipase C, leading to an influx of calcium ions (Ca2+) into the cytosol [15]. Elevated Ca2+ levels result

Fabrication of nanocrystal forms of ᴅ-cycloserine and their application for transdermal and enteric drug delivery systems

• Hsuan-Ang Tsai,
• Tsai-Miao Shih,
• Theodore Tsai,
• Jhe-Wei Hu,
• Yi-An Lai,
• Jui-Fu Hsiao and
• Guochuan Emil Tsai

Beilstein J. Nanotechnol. 2024, 15, 465–474, doi:10.3762/bjnano.15.42

• Biobehavioral Sciences, UCLA School of Medicine, 10833 Le Conte Ave, Los Angeles, CA 90095, USA 10.3762/bjnano.15.42 Abstract ᴅ-cycloserine (DCS), an FDA-approved medicine for the treatment of tuberculosis, is also a partial agonist at the glycine recognition site of N-methyl-ᴅ-aspartate (NMDA) receptor and

• the treatment of CNS disorders. Keywords: ᴅ-cycloserine; drug delivery system; enteric capsules; N-methyl-ᴅ-aspartate; nanocrystals; NMDA receptor agonist; transdermal reservoir; Introduction Tuberculosis (TB) is a prevalent respiratory disease caused by Mycobacterium tuberculosis. According to the

• studied over the last three decades, primarily due to its centrally active partial agonism of N-methyl-ᴅ-aspartate (NMDA) receptor [3][4][5][6][7][8][9][10][11][12]. Several researches indicated that DCS is a potential drug candidate to treat CNS disorders such as depression, schizophrenia, Alzheimer's

Alteration of nanomechanical properties of pancreatic cancer cells through anticancer drug treatment revealed by atomic force microscopy

• Xiaoteng Liang,
• Shuai Liu,
• Xiuchao Wang,
• Dan Xia and
• Qiang Li

Beilstein J. Nanotechnol. 2021, 12, 1372–1379, doi:10.3762/bjnano.12.101

• /or the cytoskeleton, which cause cancer cell death [8][9]. Fang et al. found that N-methyl-ᴅ-aspartate (NMDA) binding to NMDA receptors on cell membranes will increase the overall contractile forces in the cytoskeleton, thus increasing the pre-existing mechanical stress [10]. Yun et al. reported that

Transient coating of γ-Fe₂O₃ nanoparticles with glutamate for its delivery to and removal from brain nerve terminals

• Konstantin Paliienko,
• Artem Pastukhov,
• Michal Babič,
• Daniel Horák,
• Olga Vasylchenko and
• Tatiana Borisova

Beilstein J. Nanotechnol. 2020, 11, 1381–1393, doi:10.3762/bjnano.11.122

• [39]. The neuronal release of glutamate modulates the blood–brain barrier function, through activation of N-methyl-ᴅ-aspartate (NMDA) receptors [40]. Glutamate increased intracellular calcium levels in endothelial cells and levels of nitrogen oxide (NO) around microvessels. These results can be